C. Lowell Parsons
Founder bei Vaneltix Pharma, Inc.
Profil
C.
Lowell Parsons is the founder of Vaneltix Pharma, Inc. which was founded in 1997.
He holds the title of Co-Chairman & President at Vaneltix Pharma, Inc. Dr. Parsons's current job is as a Professor at the University of California San Diego, where he starts in 1988.
Dr. Parsons's former job was as a Director at Valentis, Inc. Dr. Parsons obtained a doctorate degree from Yale School of Medicine in 1970.
Aktive Positionen von C. Lowell Parsons
| Unternehmen | Position | Beginn |
|---|---|---|
Vaneltix Pharma, Inc.
 Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | Founder | 01.01.1997 |
| University of California San Diego | Corporate Officer/Principal | 28.10.2011 |
Ehemalige bekannte Positionen von C. Lowell Parsons
| Unternehmen | Position | Ende |
|---|---|---|
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Director/Board Member | 31.07.2007 |
Ausbildung von C. Lowell Parsons
| Yale School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | Health Technology |
